This slide deck covers the neurobiology and aetiology of Parkinson’s Disease. The foundational neurobiology underlying Parkinson’s disease is established alongside the routes of pathogenesis. This includes information about dopaminergic cell loss, alpha synuclein aggregation and deposition throughout the body, as well as Braak staging. Genetic and environmental factors, as well as common underlying molecular pathways underlying the development of Parkinson’s disease are also explored. The slides also examine potential targets and methods for future disease-modifying therapies.

This slide deck was developed by Shen-Yang Lim, Neurologist and Professor at the University of Malaya, Kuala Lumpur, Malaysia, and Emil Gustavsson, Senior Research Fellow at University College London, in collaboration with Cambridge (a division of Prime, Cambridge, UK).

Index for
slide deck

Intro

Neurobiology and aetiology

Neurobiology and aetiology

file_download Download slide in HQ

Neurobiology

Neurobiology

Neurobiology

file_download Download slide in HQ
The motor cortex

The motor cortex

Motor activity is controlled by projections that range from the primary motor cortex and the premotor cortical areas of the frontal lobe through to the brainstem and spinal cord.3 The primary motor cortex has an important function in the execution of distinct, well-define…

file_download Download slide in HQ
The basal ganglia

The basal ganglia

Normal motor function is the result of complex and intricate interactions between the basal ganglia, the cerebellum, and the cerebral cortex.3 The main function of the basal ganglia is to initiate motor activity and to control cortical outputs – indirectly through the tha…

file_download Download slide in HQ
The direct and indirect motor pathways

The direct and indirect motor pathways

Direct motor pathway mechanism (facilitates movement)

The direct motor pathway goes from the striatum to the globus pallidus internus (GPi) via fibres that inhibit GPi activity.1,2 When this occurs, the GPi no longer inhibits the thalamus, which is now able to send an exc…

file_download Download slide in HQ
Neurotransmitters and the synapse

Neurotransmitters and the synapse

Cells of the nervous system communicate with each other at synapses, either via electrical signals or by the release of messenger molecules called neurotransmitters.1,2 Examples of neurotransmitters include: acetylcholine, adrenaline, dopamine, serotonin, glutamate, and h…

file_download Download slide in HQ
The role of dopamine in the brain

The role of dopamine in the brain

Dopamine is an excitatory neurotransmitter present in the neurons of several regions of the central nervous system.1,2 A major dopamine-containing area is the striatum, which plays a central role in the coordination of body movements.1,2 In addition to the striatum, dopam…

file_download Download slide in HQ

The pathogenesis of Parkinson’s disease

The pathogenesis of Parkinson’s disease

The pathogenesis of Parkinson’s disease

file_download Download slide in HQ
Lewy bodies

Lewy bodies

Lewy bodies are mostly comprised of abnormal, misfolded protein, and are found in the nerve cells of most patients with PD.1,4 The function of Lewy bodies in the pathogenesis of PD is still unclear, as they have been associated with both neuroprotection and toxicity.1,4 A…

file_download Download slide in HQ
α-synuclein

α-synuclein

The protein α-synuclein was first isolated from human brain tissue during the early 1990s.10 Its role in PD only became apparent in 1997, when a mutation in the α-synuclein gene was discovered in groups of patients with a rare, autosomal dominant form of familial parkinso…

file_download Download slide in HQ
Dopaminergic cell loss in Parkinson’s disease

Dopaminergic cell loss in Parkinson’s disease

The overall level of atrophy of brain tissue does not seem to differ between patients with PD and age-matched controls.2 However, by the time a patient with PD develops motor symptoms, they will have suffered a moderate-to-severe loss of neuromelanin-pigmented, dopamine-p…

file_download Download slide in HQ
Braak staging of Parkinson’s disease

Braak staging of Parkinson’s disease

At a physiological level, PD is characterized by the loss of neurons in specific regions of the brain and a spreading of Lewy pathology.2 However, these do not necessarily always go together; many regions with a concentration of Lewy pathology show only mild neuronal loss…

file_download Download slide in HQ
Distribution of α-synuclein pathology in Parkinson’s disease

Distribution of α-synuclein pathology in Parkinson’s disease

The Lewy pathology and aggregated α-synuclein proteins associated with PD are not confined to the central nervous system (CNS); they can also be found in the peripheral nervous system at various sites around the body, such as the skin, gastrointestinal tract, and salivary…

file_download Download slide in HQ
The gastrointestinal system and Parkinson’s disease

The gastrointestinal system and Parkinson’s disease

Neurons found in the enteric (gut) nervous system (ENS) require dopamine.1 Without dopamine, these neurons cannot properly control gastrointestinal motility.1 Animal studies have suggested that the ENS may be vulnerable to degeneration during PD, and the finding of Lewy p…

file_download Download slide in HQ
The ‘body-first’ versus the ‘brain-first’ aetiology of PD

The ‘body-first’ versus the ‘brain-first’ aetiology of PD

Several lines of evidence now support the idea that there are different aetiological subtypes of PD – the body-first and the brain-first types, as outlined on the slide.1,2 In other words, the α‑synuclein pathology that characterizes PD can arise in the olfactory bulb of …

file_download Download slide in HQ

Related content

image Image Image showing mechanisms for targeting α-synuclein in Parkinson’s disease research
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Image showing potential effects of disease-modifying treatments on Parkinson’s disease progression
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease
image Image Image showing how COMT inhibitors increase dopamine availability
Catechol-O-methyltransferase (COMT) inhibitors mechanism of action

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

26.06.2025 Parkinson’s Disease